Drug Trial Radar · NCT07604311
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
288
Planned (sponsor's estimate)
Start
Jun 23, 2026
Primary completion
Dec 1, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IgA nephropathy (IgAN) is a chronic progressive kidney disease, and long-term control of proteinuria and prevention of relapse are crucial for delaying disease progression. Patients with IgAN who achieve proteinuria remission after receiving Nefecon for 9 months or longer still face the risk of proteinuria relapse after treatment discontinuation. This study is to evaluate the efficacy and safety of Nefecon 8 mg treatment for 15 months as a maintenance therapy to reduce the risk of IgAN relapse in proteinuria-remitted patients.
Conditions
- IgA Nephropathy (IgAN)
Interventions
NEFECONDrug
NEFECON 8mg once daily by mouth for 15 months
PlaceboDrug
Placebo oral capsule once daily by mouth for 15 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first composite disease relapseTime frame: 15 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanfang hospital, Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.